Why Nvidia's Cheap AI Chip for China Matters
After winning key supply deals in Saudi Arabia, Nvidia (NVDA) will not miss out on the Chinese market. The firm will reportedly launch new chips for artificial intelligence for China-based firms.In April, the Trump administration reviewed Biden-era AI chip restrictions on China. To grow its sales, Nvidia needed a low-cost product that had lower performance. It will have a GPU solution that belongs to Blackwell architecture. These chips will have a price in the range of $6,500 and $8,000, according to Reuters. By comparison, H20 solutions sell for between $10,000 and $12,000.Nvidia’s low-cost chip matters to its bottom line. China is still a meaningful contributor to its revenues. It accounted for 13% of sales in the last year. U.S. export restrictions would help Chinese chip suppliers like Huawei thrive. Since Nvidia GPUs are better and more efficient, Chinese tech firms would prefer them.AI DevelopmentsLate last month, Alibaba (BABA) released a next-generation large language model. The open-sourced LLM is a breakthrough in AI. Qwen3 has better reasoning, multilingual task support, and instruction following. More importantly, Qwen3 uses a hybrid reasoning model. This combines LLM capabilities with advanced, dynamic reasoning.Tencent (TCEHY) is not under pressure to buy more AI chips. The firm already stockpiled plenty of H20 chips for its AI developmental needs.Baidu (BIDU) is performing well, too. It reported strong AI cloud growth in the first quarter.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


